IQVIA Holdings Inc. IQV

Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

• Zacks Investment Research 2 oct

  Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

  IQVIA reported Q2 2026 adjusted EPS of $3.15, up 12.1% YoY and beating consensus by 4.3%, with revenues of $4.37B up 8.7% and exceeding estimates. R&D Solutions new bookings surged 19% to $3.2B. However, the company faces liquidity concerns with a current ratio of 0.71 and net leverage at 3.6X adjusted EBITDA.

  

• GlobeNewswire Inc. 25 sept

  AI in Clinical Trials Market Set for Transformative Growth Through 2040, Unlocking Opportunities Across Trial Phases, Therapeutic Areas, End Users and Key Global Regions

  The global AI in clinical trials market is projected to expand from USD 2.09 billion in 2026 to USD 18.62 billion by 2040, growing at a 17.0% CAGR. AI applications including patient recruitment, predictive analytics, digital twins, and automation are addressing key challenges in drug development timelines and trial efficiency. Oncology represents the largest therapeutic area, while Asia-Pacific shows significant growth potential. Key players include IQVIA, Medidata, Dassault Systemes, and emerging AI companies like Deep 6 AI and AiCure.

  

• GlobeNewswire Inc. 24 sept

  Europe Clinical Data Analytics Market Outlook 2026-2033 | AI, Cloud Deployment and Data-Driven Healthcare Adoption Accelerate Across the Region

  Europe's clinical data analytics market is projected to reach USD 105.6 billion by 2031, growing at a 27% CAGR through 2033. Growth is driven by healthcare digitalization, AI adoption, cloud deployment, and regulatory initiatives like the European Health Data Space. Software and cloud-based solutions lead the market, with healthcare providers and payers increasingly investing in analytics for improved patient outcomes and operational efficiency.

  

• GlobeNewswire Inc. 21 sept

  Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook

  The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.

  

• Zacks Investment Research 16 sept

  IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

  IQVIA (IQV) has surged 60.1% over six months, driven by 6% organic growth in Q2 2026, with R&DS bookings up 19.3% and a $34.2 billion backlog. The company's rapid AI adoption—294 agents deployed across 90 use cases with 19 of top 20 pharma companies adopting solutions—is strengthening its competitive position and supporting sustained growth.